FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our
"Question of the Day" right now.
TRADER RADAR Which stock should be on your screen? Follow the clues to solve this puzzle.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
EMERGING MONEY TOP 20
Fast Money's index for the world.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
Biotech companies will likely be one of the few bright spots for investors this earnings season, says CNBC’s Pharmaceuticals Reporter Mike Huckman, with demand for their drugs unchanged by the economy, credit crunch or mortgage meltdown.
Large-cap biotechnology companies, whose shares have outperformed an overall weak market during the second quarter, are poised to meet or beat Wall Street profit forecasts, according to most analysts. And right now all eyes are on Genentech [DNA
Loading...
()
] the world's biggest biotech by market cap.
Is the trade ahead of this biotech bellwether's earnings already done? As always, it's not the EPS number that moves the stock, explains Huckman, it's sales of Genentech's top four products especially the cancer drug Avastin.
So write down this number, he counsels. As of Thursday the Street is looking for $645 million in Avastin sales. Only time will tell.
I think a lot of the expectations are built into the stock, muses Pete Najarian. I’d wait and buy DNA on a pull back. Don’t get ahead of yourself. Also in the space Elan [ELN
Loading...
()
] is worth watching for it’s Alzheimer’s drug.
And the Celgene [CELG
Loading...
()
] story still works, adds Guy Adami.
Check Out These Other Posts |
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to .
Trader disclosure: On July 10, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Adami Owns (AGU), (C), (GS), (INTC), (MSFT), (NUE), (BTU); Macke Owns (MSFT), (USO), (INTC), (WMT); Najarian Owns (AAPL), (CHK), (MAR), (NOK), (TSO), (XTO), (XLF); Najarian Owns (FNM) And (FNM) Puts; Najarian Owns (YHOO) Calls, (RIMM) Calls, (SLB) Calls, (CSCO) Calls; GE Is The Parent Company Of CNBC; NBC Universal Is The Parent Company Of CNBC; Finerman Owns (GS); Finerman's Firm Owns (DVA), (GE), (MSFT), (NOK), (SUN), (TSO), (VLO); Finerman's Firm And Finerman Own (C) And (C) Leaps; Finerman's Firm Owns (PLCE) Calls, (TGT) Calls, (HUN) Calls.; Finerman's Firm Is Short (IJR), (MDY), (SPY), (IWM); Finerman's Firm Is Long SPX Index Puts; Finerman's Firm Is Short (BIG)
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes